成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. Metabolic Enzyme/Protease Autophagy
  2. FXR Endogenous Metabolite Autophagy
  3. Chenodeoxycholic Acid

Chenodeoxycholic Acid  (Synonyms: 鵝去氧膽酸; CDCA)

目錄號: HY-76847 純度: 99.90%
COA 產品使用指南

Chenodeoxycholic Acid 是一種疏水初級膽汁酸,能夠活化核受體 FXR,該受體與膽固醇代謝有關。

MCE 的所有產品僅用作科學研究或藥證申報,我們不為任何個人用途提供產品和服務

Chenodeoxycholic Acid Chemical Structure

Chenodeoxycholic Acid Chemical Structure

CAS No. : 474-25-9

1.  客戶無需承擔相應的運輸費用。

2.  同一機構(單位)同一產品試用裝僅限申領一次,同一機構(單位)一年內

     可免費申領三個不同產品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數量
10 mM * 1 mL in DMSO ¥550
In-stock
100 mg ¥500
In-stock
500 mg ¥700
In-stock
1 g ¥900
In-stock
5 g ¥1300
In-stock
10 g   詢價  
50 g   詢價  

* Please select Quantity before adding items.

Customer Review

  • 生物活性

  • 實驗參考方法

  • 純度 & 產品資料

  • 參考文獻

生物活性

Chenodeoxycholic Acid is a hydrophobic primary bile acid that activates nuclear receptors (FXR) involved in cholesterol metabolism.

IC50 & Target

Human Endogenous Metabolite

 

細胞效力
(Cellular Effect)
Cell Line Type Value Description References
A549 IC50
> 200 μM
Compound: CDCA
Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay
Anticancer activity against human A549 cells assessed as inhibition of cell proliferation by MTT assay
[PMID: 36439975]
Caco-2 IC50
106 μM
Compound: CDCA
Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human Caco2 cells assessed as cell viability after 24 hrs by MTT assay
[PMID: 24332653]
CHO EC50
15.6 μM
Compound: CDCA
Agonist activity at recombinant human TGR5 expressed in CHO cells assessed as increase in cAMP accumulation after 30 mins by TR-FRET assay
Agonist activity at recombinant human TGR5 expressed in CHO cells assessed as increase in cAMP accumulation after 30 mins by TR-FRET assay
[PMID: 31268316]
CHO EC50
6.71 μM
Compound: 4, CDCA
Agonist activity at human TGR5 expressed in CHO cells by luciferase assay
Agonist activity at human TGR5 expressed in CHO cells by luciferase assay
[PMID: 18307294]
CHO EC50
6.71 μM
Compound: 2, CDCA
Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay
Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay
[PMID: 17685603]
COS-1 EC50
13 μM
Compound: 4, CDCA
Agonist activity at human FXR expressed in COS1 cells by luciferase assay
Agonist activity at human FXR expressed in COS1 cells by luciferase assay
[PMID: 18307294]
COS-1 EC50
13 μM
Compound: 2, CDCA
Agonist activity at human FXR expressed in COS1 cells after 5 hrs by CRE-driven luciferase reporter gene assay
Agonist activity at human FXR expressed in COS1 cells after 5 hrs by CRE-driven luciferase reporter gene assay
[PMID: 17685603]
COS-1 EC50
13 μM
Compound: 3, CDCA
Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay
Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay
[PMID: 20014870]
GBM IC50
> 50 μM
Compound: 1c, CDCA, chenodeoxycholic acid
Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay
Cytotoxicity against human GBM cells after 24 hrs by neutral red uptake assay
[PMID: 20381215]
HCT-116 IC50
> 200 μM
Compound: CDCA
Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay
Anticancer activity against human HCT-116 cells assessed as inhibition of cell proliferation by MTT assay
[PMID: 36439975]
HCT-116 IC50
> 50 μM
Compound: 1c, CDCA, chenodeoxycholic acid
Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay
Cytotoxicity against human HCT116 cells after 24 hrs by neutral red uptake assay
[PMID: 20381215]
HEK293 EC50
11.7 μM
Compound: 3, CDCA
Agonist activity at human recombinant FXR by transactivation of TK-MH100x4-LUC reporter gene in HEK293 cells
Agonist activity at human recombinant FXR by transactivation of TK-MH100x4-LUC reporter gene in HEK293 cells
[PMID: 16617018]
HEK293 EC50
16.8 μM
Compound: CDCA
Agonist activity at full length mouse FXR/RXRalpha expressed in human HEK293 cells assessed as induction of transcriptional activity after 18 hrs by dual luciferase reporter gene assay
Agonist activity at full length mouse FXR/RXRalpha expressed in human HEK293 cells assessed as induction of transcriptional activity after 18 hrs by dual luciferase reporter gene assay
[PMID: 22014750]
HEK293 EC50
16.8 μM
Compound: 2, CDCA
Agonist activity at mouse FXR expressed in HEK293 cells co-expressing mouse RXRalpha and ECRE-luc by luciferase reporter gene assay
Agonist activity at mouse FXR expressed in HEK293 cells co-expressing mouse RXRalpha and ECRE-luc by luciferase reporter gene assay
[PMID: 22018919]
HEK293 EC50
27 μM
Compound: 5, CDCA
Agonist activity at human recombinant FXR expressed in HEK293 cells coexpressing CMX-GAL4N by luciferase reporter gene assay
Agonist activity at human recombinant FXR expressed in HEK293 cells coexpressing CMX-GAL4N by luciferase reporter gene assay
[PMID: 22583617]
HEK293 EC50
27 μM
Compound: CDCA
Agonistic activity at FXR in HEK293 cells by GAL4 transactivation activity
Agonistic activity at FXR in HEK293 cells by GAL4 transactivation activity
[PMID: 17292610]
HEK293 EC50
6.1 μM
Compound: 2, CDCA
Agonist activity at human GPBAR1 expressed in HEK293 cells assessed as increase in intracellular cAMP level after 30 mins by cAMP-Glo assay
Agonist activity at human GPBAR1 expressed in HEK293 cells assessed as increase in intracellular cAMP level after 30 mins by cAMP-Glo assay
[PMID: 25735208]
HEK-293T EC50
> 150 μM
Compound: CDCA
Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay
Agonist activity at VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay
[PMID: 26774929]
HEK-293T IC50
> 50 μM
Compound: CDCA
Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay
Antagonist activity against VP16 tagged-VDR-LBD (unknown origin) expressed in HEK293T cells assessed as inhibition of 1,25-dihydroxyvitamin D3-induced SRC1 coactivator peptide recruitment after 16 hrs by luciferase reporter gene based two hybrid assay
[PMID: 26774929]
HeLa EC50
18 μM
Compound: 1, CDCA
Agonist activity at human full length FXR expressed in HeLa cells cotransfected with pSG5-human RXR after 24 hrs by Dual-Glo luciferase reporter gene assay
Agonist activity at human full length FXR expressed in HeLa cells cotransfected with pSG5-human RXR after 24 hrs by Dual-Glo luciferase reporter gene assay
[PMID: 25934227]
HeLa EC50
18 μM
Compound: 1, CDCA
Agonist activity at human FXR expressed in human HeLa cells assessed as receptor activation by BSEP promoter-driven firefly luciferase reporter gene assay
Agonist activity at human FXR expressed in human HeLa cells assessed as receptor activation by BSEP promoter-driven firefly luciferase reporter gene assay
[PMID: 25255039]
HepG2 EC50
20 μM
Compound: 1; CDCA
Transactivation of human FXR (unknown origin) expressed in HepG2 cells co-expressing pSG5RXR/pGL4.70 after 24 hrs post transfection by luciferase reporter gene assay
Transactivation of human FXR (unknown origin) expressed in HepG2 cells co-expressing pSG5RXR/pGL4.70 after 24 hrs post transfection by luciferase reporter gene assay
[PMID: 30996771]
HET-1A CC50
216 μM
Compound: 1, CDCA
Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human HET-1A cells assessed as cell viability after 24 hrs by MTT assay
[PMID: 20713311]
HT-1080 IC50
130.1 μM
Compound: CDCA
Cytotoxicity against human HT1080 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human HT1080 cells assessed as cell viability after 24 hrs by MTT assay
[PMID: 24332653]
HT-29 IC50
> 200 μM
Compound: CDCA
Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay
Anticancer activity against human HT-29 cells assessed as inhibition of cell proliferation by MTT assay
[PMID: 36439975]
HT-29 IC50
> 80 μM
Compound: CDCA
Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay
Antiproliferative activity against human HT-29 cells after 48 hrs by SRB assay
[PMID: 27448915]
Huh-7 IC50
> 200 μM
Compound: CDCA
Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation by MTT assay
Anticancer activity against human Huh-7 cells assessed as inhibition of cell proliferation by MTT assay
[PMID: 36439975]
KMS-11 IC50
> 50 μM
Compound: 1c, CDCA, chenodeoxycholic acid
Cytotoxicity against human KMS11 cells after 24 hrs by neutral red uptake assay
Cytotoxicity against human KMS11 cells after 24 hrs by neutral red uptake assay
[PMID: 20381215]
LoVo IC50
> 200 μM
Compound: CDCA
Anticancer activity against human LoVo cells assessed as inhibition of cell proliferation by MTT assay
Anticancer activity against human LoVo cells assessed as inhibition of cell proliferation by MTT assay
[PMID: 36439975]
MGC-803 IC50
> 200 μM
Compound: CDCA
Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation by MTT assay
Anticancer activity against human MGC-803 cells assessed as inhibition of cell proliferation by MTT assay
[PMID: 36439975]
NCI-H716 EC50
30 μM
Compound: 1, CDCA
Agonist activity at human TGR5 receptor expressed in NCI-H716 cells assessed as intracellular cAMP level by TR-FRET assay
Agonist activity at human TGR5 receptor expressed in NCI-H716 cells assessed as intracellular cAMP level by TR-FRET assay
[PMID: 21459580]
NCI-H716 EC50
33 μM
Compound: CDCA
Agonist activity at TGR5 in human NCI-H716 cells assessed as increase in cAMP accumulation after 60 mins by HTR-FRET assay
Agonist activity at TGR5 in human NCI-H716 cells assessed as increase in cAMP accumulation after 60 mins by HTR-FRET assay
[PMID: 31268316]
NCI-H716 EC50
6.7 μM
Compound: 2, CDCA
Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis
Agonist activity at TGR5 expressed in NCI-H716 cells assessed as cAMP level after 60 mins by FRET analysis
[PMID: 24900463]
PC-3M IC50
> 80 μM
Compound: CDCA
Antiproliferative activity against human PC3M cells after 48 hrs by SRB assay
Antiproliferative activity against human PC3M cells after 48 hrs by SRB assay
[PMID: 27448915]
RKO IC50
> 200 μM
Compound: CDCA
Anticancer activity against human RKO cells assessed as inhibition of cell proliferation by MTT assay
Anticancer activity against human RKO cells assessed as inhibition of cell proliferation by MTT assay
[PMID: 36439975]
SK-HEP1 IC50
> 200 μM
Compound: CDCA
Anticancer activity against human SK-HEP1 cells assessed as inhibition of cell proliferation by MTT assay
Anticancer activity against human SK-HEP1 cells assessed as inhibition of cell proliferation by MTT assay
[PMID: 36439975]
SW480 IC50
> 200 μM
Compound: CDCA
Anticancer activity against human SW480 cells assessed as inhibition of cell proliferation by MTT assay
Anticancer activity against human SW480 cells assessed as inhibition of cell proliferation by MTT assay
[PMID: 36439975]
體外研究
(In Vitro)

Cheonodeoxycholic acid (CDCA) 和 Deoxycholic acid (DCA) 均抑制 11 beta HSD2,IC50 值分別為 22 mM 和 38 mM,并引起皮質醇依賴性核轉位并增加鹽皮質激素受體 (MR) 的轉錄活性)[1]。Cheonodeoxycholic acid 能夠通過激活膜 G 蛋白偶聯受體 (TGR5) 依賴性通路誘導細胞周期蛋白 D1 蛋白和 mRNA 表達顯著增加,從而刺激 Ishikawa 細胞生長[2]。在培養(yǎng)的人肝母細胞瘤細胞系 Hep G2[3]中,Chenodeoxycholic Acid (CDCA) 可將 LDL 受體 mRNA 水平提高約 4 倍,將 HMG-CoA 還原酶和 HMG-CoA 合酶的 mRNA 水平提高兩倍。布美他尼、BaCl2 和囊性纖維化跨膜電導調節(jié)劑 (CFTR) 抑制劑 CFTRinh-172 可抑制鵝脫氧膽酸誘導的 Isc (≥67%)。Chenodeoxycholic Acid 刺激的 Isc 被腺苷酸環(huán)化酶抑制劑 MDL12330A 降低了 43%,而 Chenodeoxycholic Acid 增加了細胞內 cAMP 濃度[4]。Chenodeoxycholic Acid 處理可激活 C/EBPβ,如其在 HepG2 細胞中的磷酸化、核積累和表達增加所示。Cheonodeoxycholic acid 增強熒光素酶基因從含有-1.65-kb GSTA2 啟動子的構建體轉錄,該啟動子含有 C/EBP 反應元件 (pGL-1651)。Chenodeoxycholic Acid 處理可激活 AMP 活化蛋白激酶 (AMPK),從而導致細胞外信號調節(jié)激酶 1/2 (ERK1/2) 激活,使用 AMPKα 顯性失活突變體和化學抑制劑的實驗結果證明了這一點[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
分子量

392.57

Formula

C24H40O4

CAS 號
性狀

固體

顏色

White to off-white

中文名稱

鵝去氧膽酸

結構分類
初始來源
運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式

RT, protect from light

In solvent -80°C 2 years
-20°C 1 year
溶解性數據
細胞實驗: 

DMSO 中的溶解度 : ≥ 50 mg/mL (127.37 mM; 吸濕的 DMSO 對產品的溶解度有顯著影響,請使用新開封的 DMSO)

0.1 M NaOH 中的溶解度 : 50 mg/mL (127.37 mM; ultrasonic and adjust pH to 8 with NaOH)

* "≥" means soluble, but saturation unknown.

配制儲備液
濃度 溶劑體積 質量 1 mg 5 mg 10 mg
1 mM 2.5473 mL 12.7366 mL 25.4732 mL
5 mM 0.5095 mL 2.5473 mL 5.0946 mL
查看完整儲備液配制表

* 請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復凍融造成的產品失效
儲備液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C儲存時,請在2年內使用,-20°C儲存時,請在1年內使用。

  • 摩爾計算器

  • 稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動物實驗:

請根據您的 實驗動物和給藥方式 選擇適當的溶解方案。

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液,再依次添加助溶劑:
——為保證實驗結果的可靠性,澄清的儲備液可以根據儲存條件,適當保存;體內實驗的工作液,建議您現用現配,當天使用
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比;如在配制過程中出現沉淀、析出現象,可以通過加熱和/或超聲的方式助溶

  • 方案 一

    請依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.5 mg/mL (6.37 mM); 懸濁液; 超聲助溶

    此方案可獲得 2.5 mg/mL的均勻懸濁液,懸濁液可用于口服和腹腔注射。

    1 mL 工作液為例,取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中,混合均勻;再向上述體系中加入 50 μL Tween-80,混合均勻;然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

    生理鹽水的配制:將 0.9 g 氯化鈉,溶解于 ddH?O 并定容至 100 mL,可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請依序添加每種溶劑: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (6.37 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL(飽和度未知)的澄清溶液。

    1 mL 工作液為例,取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中,混合均勻。

    2 g SBE-β-CD(磺丁基醚 β-環(huán)糊精)粉末定容于 10 mL 的生理鹽水中,完全溶解至澄清透明。

以下溶解方案,請直接配制工作液。建議現用現配,在短期內盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比; 如在配制過程中出現沉淀、析出現象,可以通過加熱和/或超聲的方式助溶。

  • 方案 一

    請依序添加每種溶劑: 20% HP-β-CD in Saline

    Solubility: ≥ 20 mg/mL (50.95 mM); 澄清溶液

動物溶解方案計算器
請輸入動物實驗的基本信息:

給藥劑量

mg/kg

動物的平均體重

g

每只動物的給藥體積

μL

動物數量

由于實驗過程有損耗,建議您多配一只動物的量
請輸入您的動物體內配方組成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的動物是免疫缺陷鼠或者體弱鼠,建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
方案所需 助溶劑 包括:DMSO, ,均可在 MCE 網站選購。 ,Tween 80,均可在 MCE 網站選購。
計算結果
工作液所需濃度 : mg/mL
儲備液配制方法 : mg 藥物溶于 μL  DMSO(母液濃度為 mg/mL)。
您所需的儲備液濃度超過該產品的實測溶解度,以下方案僅供參考,如有需要,請與 MCE 中國技術支持聯系。
動物實驗體內工作液的配制方法 : 取 μL DMSO 儲備液,加入 μL 。 μL ,混合均勻至澄清,再加 μL Tween 80,混合均勻至澄清,再加 μL 生理鹽水
連續(xù)給藥周期超過半月以上,請謹慎選擇該方案。
請確保第一步儲備液溶解至澄清狀態(tài),從左到右依次添加助溶劑。您可采用超聲加熱 (超聲清洗儀,建議頻次 20-40 kHz),渦旋吹打等方式輔助溶解。
純度 & 產品資料

純度: 99.90%

參考文獻
Kinase Assay
[1]

Briefly, transfected HEK-293 cells, incubated in charcoal-treated Dulbecco's modified Eagle's medium for 24 h, are washed once with Hanks' solution and resuspended in a buffer containing 100 mM NaCl, 1 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 250 mMsucrose, 20 mM Tris-HCl, pH 7.4. Cells are lysed by freezing in liquid nitrogen. Dehydrogenase activity is measured in a final volume of 20 μL containing the appropriate concentration of bile acid, 30 nCi of [3H]cortisol, and unlabeled cortisol to a final concentrations of 50 nM. The reaction is started by mixing cell lysate with the reaction mixture. Alternatively, endoplasmic reticulum microsomes are prepared from transfected HEK-293 cells and incubated with reaction mixture containing various concentrations of cortisol and CDCA. Incubation proceeded for 20 min, and the conversion of cortisol to cortisone is determined by thin layer chromatography (TLC). Because of the inaccuracy of the TLC method at low conversion rates and the end-product inhibition of 11βHSD2 at conversion rates higher than 60-70%, only conversion rates between 10 and 60% are considered for calculation. The inhibitory constant IC50 is evaluated using the curve-fitting program. Results are expressed as means±S.E. and consist of at least four independent measurements.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[1]

The cell viability is analyzed by incubating transfected HEK-293 cells and CHO cells for 1 h with the corresponding concentration of bile acid and staining with trypan blue. The toxicity of bile acids is analyzed using the tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) according to the cell proliferation kit I. No significant differences between control and bile acid-treated cells are obtained in both tests.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

參考文獻

完整儲備液配制表

* 請根據產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復凍融造成的產品失效。
儲備液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C儲存時,請在2年內使用,-20°C儲存時,請在1年內使用。

可選溶劑 濃度 溶劑體積 質量 1 mg 5 mg 10 mg 25 mg
DMSO / 0.1 M NaOH 1 mM 2.5473 mL 12.7366 mL 25.4732 mL 63.6829 mL
5 mM 0.5095 mL 2.5473 mL 5.0946 mL 12.7366 mL
10 mM 0.2547 mL 1.2737 mL 2.5473 mL 6.3683 mL
15 mM 0.1698 mL 0.8491 mL 1.6982 mL 4.2455 mL
20 mM 0.1274 mL 0.6368 mL 1.2737 mL 3.1841 mL
25 mM 0.1019 mL 0.5095 mL 1.0189 mL 2.5473 mL
30 mM 0.0849 mL 0.4246 mL 0.8491 mL 2.1228 mL
40 mM 0.0637 mL 0.3184 mL 0.6368 mL 1.5921 mL
50 mM 0.0509 mL 0.2547 mL 0.5095 mL 1.2737 mL
60 mM 0.0425 mL 0.2123 mL 0.4246 mL 1.0614 mL
80 mM 0.0318 mL 0.1592 mL 0.3184 mL 0.7960 mL
100 mM 0.0255 mL 0.1274 mL 0.2547 mL 0.6368 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產品:

Your information is safe with us. * Required Fields.

   產品名稱:

 

* 需求量:

* 客戶姓名:

 

* Email:

* 電話:

 

* 公司或機構名稱:

   留言給我們:

Bulk Inquiry

Inquiry Information

產品名稱:
Chenodeoxycholic Acid
目錄號:
HY-76847
需求量: